Lannett Company, Inc.

OTCPK:LCIN.Q Stock Report

Market Cap: US$319.2k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lannett Company Management

Management criteria checks 3/4

Lannett Company's CEO is Tim Crew, appointed in Jan 2018, he has a tenure of 5.42 years. His total yearly compensation is $3.53M , comprised of 21.9% salary and 78.1% bonuses, including company stock and options. He directly owns 1.4% of the company’s shares, worth $4.48K. The average tenure of the management team and the board of directors is 5.4 years and 5.2 years respectively.

Key information

Tim Crew

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage21.87%
CEO tenure5.4yrs
CEO ownership1.4%
Management average tenure5.4yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Seeking Alpha • Jan 25

Lannett announces 1-for-4 reverse stock split

Lannett (NYSE:LCI) said its board approved a 1-for-4 reverse stock split of its issued and outstanding shares, which will be effective at 5 p.m. Eastern Time on February 6. No fractional shares will be issued in connection with the reverse stock split, the company said.
Seeking Alpha • Nov 07

Lannett gains on patent deal for biosimilar insulin device

The shares of generic drugmaker Lannett Company (NYSE:LCI) added ~9% on Monday after announcing a licensing deal for patents related to a pen injector device for its investigational biosimilar products, insulin glargine and insulin aspart. Per the terms, Lannett (LCI) and its partner HEC Group of companies will sublicense to a licensing arrangement between Ypsomed AG, the maker of the device, and Sanofi (SNY) unit Sanofi-Aventis Deutschland GmbH, which owns several patents related to the device. The financial details of the deal were not disclosed. "In short, we have significantly improved our ability to freely market our biosimilar insulin products, once approved," Lannett (LCI) Chief Executive Tim Crew remarked. The company plans to submit a marketing application for biosimilar and interchangeable insulin glargine targeting Sanofi's (SNY) Lantus in 2023 spring, expecting a potential launch in H1 2024. Last week, Lannett (LCI) exceeded Street forecasts with its Q1 financials for fiscal 2023.
Seeking Alpha • Oct 21

Lannett gets FDA approval to manufacture Numbrino® at Seymour plant

The U.S. Food and Drug Administration (FDA) approved micro-cap generic drugmaker Lannett Company (NYSE:LCI) to rapidly expand liquid drug manufacturing of Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan. NUMBRINO is indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.
Analysis Article • Sep 01

Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates

Today is shaping up negative for Lannett Company, Inc. ( NYSE:LCI ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 24

Lannett GAAP EPS of -$2.30, revenue of $74.19M

Lannett press release (NYSE:LCI): Q4 GAAP EPS of -$2.30; Non-GAAP EPS of -$0.44 Revenue of $74.19M (-30.0% Y/Y). Adjusted gross profit was $10.4 million, or 14% of net sales, compared with $26.4 million, or 25% of net sales. Negative adjusted EBITDA was $1.3 million versus adjusted EBITDA of $12.1 million. FY 2023 Guidance: Revenue expected between $275 million to $300 million; Adjusted Gross margin of approximately 15% to 17%; and Capex of approximately $8 million to $12 million.
Seeking Alpha • Feb 22

Lannett: A Self-Inflicted Crisis

Lannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price lower than the threshold necessary for listing on the NYSE, down from a record high in 2015 of $72.44, investors must wonder what happened to Lannett.
Analysis Article • Feb 05

Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts

One thing we could say about the analysts on Lannett Company, Inc. ( NYSE:LCI ) - they aren't optimistic, having just...
Analysis Article • Nov 05

A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)

How far off is Lannett Company, Inc. ( NYSE:LCI ) from its intrinsic value? Using the most recent financial data, we'll...
Analysis Article • Jun 20

Is Lannett Company (NYSE:LCI) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 18

Is Lannett Company (NYSE:LCI) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article • Feb 11

Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)

We'd be surprised if Lannett Company, Inc. ( NYSE:LCI ) shareholders haven't noticed that the Independent Director...
Analysis Article • Jan 15

What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
Analysis Article • Dec 11

Is Lannett Company (NYSE:LCI) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

CEO Compensation Analysis

How has Tim Crew's remuneration changed compared to Lannett Company's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$259m

Dec 31 2022n/an/a

-US$193m

Sep 30 2022n/an/a

-US$237m

Jun 30 2022US$4mUS$773k

-US$232m

Mar 31 2022n/an/a

-US$316m

Dec 31 2021n/an/a

-US$288m

Sep 30 2021n/an/a

-US$379m

Jun 30 2021US$4mUS$760k

-US$363m

Mar 31 2021n/an/a

-US$195m

Dec 31 2020n/an/a

-US$205m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020US$5mUS$748k

-US$33m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019n/an/a

US$3m

Jun 30 2019US$2mUS$735k

-US$272m

Mar 31 2019n/an/a

-US$276m

Dec 31 2018n/an/a

-US$274m

Sep 30 2018n/an/a

-US$272m

Jun 30 2018US$2mUS$351k

US$29m

Compensation vs Market: Tim's total compensation ($USD3.53M) is above average for companies of similar size in the US market ($USD747.42K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.

CEO

Tim Crew (62 yo)

5.4yrs
Tenure
US$3,532,372
Compensation

Mr. Timothy C. Crew, also known as Tim, has been Chief Executive Officer and Director of Lannett Company, Inc. since January 2, 2018 and January 17, 2018 respectively. Mr. Crew has more than 25 years of ex...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Crew
CEO & Director5.4yrsUS$3.53m1.4%
$ 4.5k
John Abt
VP and Chief Quality5.2yrsUS$1.00m0.28%
$ 880.8
Samuel Israel
General Counsel & Chief Legal Officer5.9yrsUS$1.22m0.36%
$ 1.2k
Maureen Cavanaugh
Senior VP & Chief Commercial Operations Officer5.1yrsUS$1.29m0.33%
$ 1.1k
Kristie Stephens
Chief Compliance Officer & VP of Regulatory Affairs6.9yrsno datano data
5.4yrs
Average Tenure
61.5yo
Average Age

Experienced Management: LCIN.Q's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Crew
CEO & Director5.4yrsUS$3.53m1.4%
$ 4.5k
Patrick LePore
Non-Executive Independent Chairman5.9yrsUS$320.00k1.36%
$ 4.4k
David Drabik
Independent Director12.4yrsUS$314.00k0.25%
$ 803.0
Jeffrey Farber
Chairman Emeritusless than a yearUS$290.00k6.65%
$ 21.2k
John Chapman
Independent Director4.9yrsUS$290.00k0.40%
$ 1.3k
Melissa Rewolinski
Independent Director3.9yrsUS$290.00k0.22%
$ 691.3
5.2yrs
Average Tenure
62.5yo
Average Age

Experienced Board: LCIN.Q's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/21 08:59
End of Day Share Price 2023/06/16 00:00
Earnings2023/03/31
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lannett Company, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research
John NewmanCanaccord Genuity